Walleye Capital’s Acceleron Pharma XLRN Stock Holding History

Walleye Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,600	Closed	-$144K	–	1101
2020 Q1	$144K	Buy	+1,600	New	+$124K	0.03%	513
2019 Q3	–	Sell	-11,700	Closed	-$481K	–	2393
2019 Q2	$481K	Buy	11,700 +2,300	+24%	+$95.2K	0.05%	508
2019 Q1	$438K	Buy	+9,400	New	+$413K	0.07%	435

Walleye Capital's XLRN Position: Q4 2021 in Review

Walleye Capital sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 22,854 shares — an estimated $3.93K sold.

Walleye Capital first reported a position in XLRN in Q1 2019 and held it in 3 quarters. The position peaked at $197K in Q1 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Walleye Capital reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 22,854 Acceleron Pharma shares in Q4 2021, an estimated $3.93K.
Walleye Capital first reported a position in Acceleron Pharma in Q1 2019 and held it in 3 quarters.
Walleye Capital's Acceleron Pharma position peaked at $197K in Q1 2020.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.